GLOW & KLOW Blends: What's Inside the Four-Peptide Combos

The GLOW and KLOW blends are the two most-asked-about pre-mixed research combinations in the catalog. They get lumped together, and the names don’t tell you the contents — this guide lists exactly what is in each vial and how the math works when you reconstitute.

What each blend contains

Blend	Vial total	Components
GLOW	70 mg	BPC-157 10mg · GHK-Cu 50mg · TB-500 10mg
KLOW	80 mg	BPC-157 10mg · GHK-Cu 50mg · TB-500 10mg · KPV 10mg

Both share the same three-component base — BPC-157, GHK-Cu and TB-500 — which is why they read as a family. KLOW extends the formulation with KPV, a three-amino-acid fragment of alpha-MSH studied for inflammatory pathway modulation.

Why pre-blend at fixed ratios

Each component has a separate research footprint: BPC-157 in angiogenesis and gastrointestinal mucosa models, TB-500 in cell-migration work around the actin-binding domain, GHK-Cu in copper-dependent collagen and tissue-remodeling studies, and KPV in anti-inflammatory signaling. Combined protocols reference these together at particular ratios — the blend fixes that ratio in a single vial so one reconstitution delivers all four at their documented masses. That removes a set of pipetting steps and keeps the ratio stable across a protocol, at the cost of not being able to titrate one component independently.

Reconstitution math

The total lyophilized mass is the sum of the components — 70mg for GLOW, 80mg for KLOW. Reconstitution follows the same rule as any peptide vial: add bacteriostatic water, divide the total by the volume for the overall concentration, and each component keeps its per-vial mass.

For GLOW at 2 mL: total concentration is 35 mg/mL, and the individual concentrations are BPC-157 5 mg/mL, GHK-Cu 25 mg/mL, TB-500 5 mg/mL. The reconstitution calculator handles the per-component math directly.

Research context

The blend concept comes from combined-protocol literature: BPC-157 and TB-500 appear together in soft-tissue repair work, and GLOW/KLOW layer in the copper peptide and the anti-inflammatory tripeptide. None of the combined formulations has phase-1 human data — the rationale is component-level, which is standard for this class of research materials.

For researchers who need independent titration, the single-compound vials remain available; the blends exist for fixed-ratio protocols.